Jacobson Pharma's IFRS net income for 6M 2022 fiscal year was HK$82.859 million, down 26.3% from HK$112.453 million in the previous year. Revenue increased 7.9% to HK$750.413 million from HK$695.425 million a year earlier.
Jacobson Pharma's IFRS net income for 6M 2022 fiscal year was HK$82.859 million, down 26.3% from HK$112.453 million in the previous year. Revenue increased 7.9% to HK$750.413 million from HK$695.425 million a year earlier. 
www1.hkexnews.hk
English (US) 